Optimization of Antisense Oligodeoxynucleotide Structure for Targeting bcr-abl mRNA by R. V. Giles et al.
Optimization of Antisense  Oligodeoxynucleotide  Structure for 
Targeting bcr-abl mRNA 
By R.V. Giles,  D.G.  Spiller, J.A.  Green, R.E. Clark, and D.M. Tidd 
Antisense  oligodeoxynucleotides  targeted to bcr-ab1  are  po- 
tential ex  vivo purging  agents  for  use with autologous  bone 
marrow transplantation  in the treatment of  chronic myeloid 
leukemia (CML). We  investigated, in a  cell-free  system, the 
activity  and  nuclease  resistance  of  phosphodiester,  phos- 
phorothioate,  chimeric  methylphosphonate/phosphodies- 
ter,  and  chimeric  methylphosphonate/phosphorothioate 
antisense  octadecamers  directed  against  either  b2a2  or b3a2 
bcr-ab1  breakpoint  RNAs.  Certain  chimeric  compounds  were 
shown to possess targeted activity broadly  equal  to the par- 
ent phosphodiester  or phosphorothioate  forms  and  greater 
resistance to  the  nucleases  present  in cell  extracts.  Selected 
chimeric  structures  were  compared with phosphodiester 
C 
HRONIC MYELOID LEUKEMIA (CML) is a serious 
neoplastic disorder of  the hematopoietic stem cell in 
which the leukemic cells carry a specific chromosomal defect 
termed the Philadelphia (Ph) chromosome. The Ph chromo- 
some is  characterized by  a translocation t(9; 22)(q34;  q 1  1) 
that results in the fusion of c-ubl and the major breakpoint 
cluster region (bcr)  genes.' Aberrant bcr-ubl transcripts de- 
rived  from  this region  consist of  a  proximal bcr-derived 
portion, terminating with exon 2 (b2) or exon 3 (b3), linked 
to a distal c-ubi derivative, exons 2 to  11 (a2). The BCR- 
ABL (p210) tyrosine kinase displays enhanced activity over 
wild-type c-ABL (~145)'  and is believed to  play a central 
role in the pathogenesis of  CML. 
Antisense oligodeoxynucleotides may potentially be used 
to modify aberrant gene expre~sion.~.~  Antisense compounds, 
with sequences complementary to the target  mRNA,  can  be 
taken up by cells from their growth media, largely into vesic- 
ular  structure^.^.^ Oligodeoxynucleotides that penetrate into 
the cell cytoplasm may hybridize to the target mRNA  and 
inefficiently inhibit translation by physical blockade of ribo- 
some function.  Alternatively, they  may  be  rapidly  trans- 
ported from the cytoplasm to  the  nucleus,'  where interaction 
with  the target site has been shown to result in specific RNA 
degradation due to the presence of  ribonuclease H (RNase 
H) activities,' an apparently ubiquitous group of  nuclear en- 
zymes that cleave the  RNA  strand in  RNA-DNA hetero- 
duplexes. 
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and  phosphorothioate  analogues  for  antisense  activity  in 
human  CML  cells  containing  either  b2a2  or  b3a2  bcr-ab1 
breakpoint rnRNAs. We  present  results  showing  that all four 
structures  can  suppress  bcr-ablmRNA level  in  vivo.  The  rank 
of in vivo activity is  chimeric methylphosphonate/phospho- 
diester z  phosphodiester > phosphorothioate > methyl- 
phosphonatelphosphorothioate.  We  show  that  b2a2 
breakpoint  RNAs  can  be more  effectively  targeted than b3a2 
sequence  RNAs  both in vitro and in vivo  and  suggest  that 
RNA  secondary  structure  may be a  possible  explanation  for 
this  phenomenon. 
0  1995 by The  American Society of Hematology. 
The effect of antisense compounds complementary to bcr- 
abi breakpoint sequences on bcr-ubi mRNA abundance and 
CML cell  proliferation has  been  investigated. The  initial 
dramatic effects'".'' have not  been  broadly  confirmed." Anti- 
sense oligodeoxynucleotides can decrease bcr-ubi transcript 
level and CML cell growth  in ~ulture,'~"~  although probably 
not  to  the degree required  to  restore Ph chromosome-nega- 
tive hematopoiesis.16 
Clearly, if  anti-bcr-ubi  oligodeoxynucleotides are to be 
clinically relevant, there is a need to improve their  potency 
and reduce toxic side effects. The precise chemistry of  an 
antisense analogue's sugar-phosphate backbone can signifi- 
cantly affect its antisense properties. The widely  used'"." 
phosphodiester oligodeoxynucleotides, which  have the same 
structure as natural DNA, have been  shown  to be  rapidly 
degraded by  the  nucleases found  in  biologic 
This nucleolytic digestion of the antisense effectors may lead 
to a lowering of  drug concentration to  half its original value 
over a period of  only minutes to hours  and  to  the release 
of  toxic  deoxynucleoside and deoxynucleotide monomers. 
Furthermore, phosphodiester effectors are potentially capa- 
ble  of  producing nonspecific biologic effects by  directing 
RNase  H  cleavage at  sites in  other RNA  molecules that 
display only  partial complementarity2"  to  the  oligodeoxy- 
nucleotide. The comparatively nuclease-resistant phosphoro- 
thioate analogues"  are also widely  but  have else- 
where  been  shown  to  induce sequence independent toxicity 
through interactions with  protein^^*^^-'^ and may  also direct 
RNase  H  activity  at  nontarget, partially  complementary, 
RNA sequences.26  Oligodeoxynucleotides that contain only 
methylphosphonate  internucleoside  linkages  have  been 
found to  be  nuclease resistantz7  but incapable of  directing 
RNase H."  Antisense effects observed with  compounds of 
this  structure cannot, therefore, be  due  to  the  RNase  H- 
mediated RNA  cleavage mechanism, in  contrast to  both 
phosphodiester  and  phosphorothioate  structures.  Further- 
more, antisense effects against mRNA necessarily generated 
by  physical obstruction of  ribosome function may  be  ex- 
pected to be particularly inefficient with methylphosphonate 
analogues because of  their  very  low  RNA  hybrid stabili- 
 tie^.'^^^ This finding means that particularly high concentra- 
tions of  such oligomers are required for sufficient target site 
occupancy  to  inhibit translation of the mRNA into protein. 
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We  have  previously  shown  that  chimeric  oligodeoxy- 
nucleotide analogues composed of terminal methylphospho- 
nate regions surrounding a central core of  phosphodiester 
residues possess the beneficial characteristics for antisense 
effectors of enhanced resistance to  exonuclease^,'^ while re- 
taining the capacity to direct RNase H?8s29  Furthemore,  we 
have shown that chimeric methylphosphonate/phosphodies- 
ter oligodeoxynucleotide analogues induce RNase H-depen- 
dent antisense effects, both in  vitro20.26 and in vivo,3o  with 
greater RNA target site selectivity than phosphodiester or 
phosphorothioate analogues and with similar, or greater, ac- 
tivity at the target site. 
The foregoing considerations suggested to us that the anti- 
sense oligodeoxynucleotide structures previously used for 
targeting bcr-ab1 may have been suboptimal. Our aim in this 
investigation was to compare a series of oligodeoxynucleo- 
tides with varying internucleoside chemistries in terms of 
their ability to  selectively and efficiently target b2a2  and 
b3a2 bcr-ab1 messenger RNA. First, a cell-free assay system 
was developed that used a human cell extract that contained 
RNase H activities and that was applied under conditions of 
physiologic ionic composition and temperature. Oligodeoxy- 
nucleotides  composed  entirely  of  phosphodiester  inter- 
nucleoside linkages or entirely of phosphorothiodiester resi- 
dues  were  tested  alongside  chimeric  methylphosphonate/ 
phosphodiester and the recently described chimeric methyl- 
phosphonate/phosphorothioate3‘ structures. We  report that 
the chimeric molecules were far superior to the phosphodies- 
ter compounds in terms of  stability to the nucleases present 
in the cell  extract. In  addition, certain of  these structures 
directed RNase  H  in  vitro with  equal  activity and  much 
greater selectivity than did either the phosphodiester or phos- 
phorothioate effectors, although some of  the more highly 
methylphosphonate-modified compounds  showed  reduced 
activity. On the basis of the in vitro work, we extended our 
investigation to intact human cells. Human CML cells were 
“biochemically  mi~roinjected”~~  with  bcr-ab1  antisense 
phosphodiester, phosphorothioate, and the chimeric methyl- 
phosphonate/phosphudiester and  methylphosphonatelphos- 
phorothioate oligodeoxynucleotides that showed the greatest 
activity in vitro to test for their in vivo activity at reducing 
the level of bcr-ab1 messenger RNAs. Of the eight antisense 
effectors tested, all but one (chimeric methylphosphonate/ 
phosphorothioate, targeted to b3a2 mRNA) induced an  anti- 
sense effect  in  vivo. We  show  that the  order of  activity 
in vivo was chimeric methylphosphonate/phosphodiester 2 
phosphodiester >  phosphorothioate >  chimeric methylphos- 
phonate/phosphorothioate. 
MATERIALS AND METHODS 
Oligodeoxynucleotide  Synthesis  and Purijcation 
Figure  1 shows the  oligodeoxynucleotides used  in  this  study. 
Phosphodiester and chimeric methylphosphonatdphosphodiester  oli- 
godeoxynucleotides were synthesized as previously reported’ using 
phosphoramidites and methyiphosphonamidites from Glen Research 
Inc (UK Supplier, Cambio, Cambridge, UK) and the slow 1 pmol 
cycle (version 1.23) on an Applied Biosystems (Warrington, Chesh- 
ire, UK) 381A DNA synthesizer, with the exception that the base 
deprotection procedure recommended by Agrawal and G~odchild~~ 
was substituted for that used by  Miller et al.”  In  our hands, the 
former short treatment with concentrated ammonia solution at room 
temperature  before  ethylenediamine/ethanol deprotection  gave  a 
much cleaner product than hydrazine hydrate, in which substantial 
base modification was observed. When Aminolink 2 (Applied Bio- 
systems) was incorporated at the 5’ end of the oligodeoxynucleotide 
as the final cycle of synthesis for subsequent attachment of  fluores- 
cein, the ammonia treatment was extended from 2 hours to 4 hours 
to ensure complete deprotection of the linker amino group. In every 
case treatment with ethylenediamine/ethanol (1 :  1 by  volume) was 
for  18 hours. 
Oligodeoxynucleotide phosphorothioates and  chimeric  methyl- 
phosphonate/phosphorothioates  were synthesized in like manner us- 
ing the Applied Biosystems 1 pmol phosphorothioate cycle (User 
Bulletin No.  58) and  tetraethylthiuram disulphide (TETD) as the 
sulphurizing reagent in place of the iodine oxidizing reagent on the 
synthesi~er.~~  Phosphorothioates were purified  by  ion  exchange high 
performance liquid chromatography (HPLC) on an  MA7 Plasmid 
column (BioRad, Hemel Hempstead, Hertfordshire, UK) to separate 
the desired products from oligomers containing failed sulphurization, 
phosphodiester linkages, which are not removed by  reverse-phase 
purification strategies, as described by  Zon.” 
Cell Culture 
The acute lymphoblastic leukemia MOLT4 (European Collection 
of  Animal Cell Cultures [ECACC], Porton Down, Wiltshire, UK) 
and chronic myeloid leukemia cell lines K562 (ECACC), KYOI, 
and LAMA84 (generous gifts of Drs M. Kirkland and S. O’Brien, 
LW  Leukaemia Unit, Hammersmith Hospital, London, UK) were 
maintained in exponential growth in RPM1 1640 medium (GIBCO, 
Paisley, Renfrewshire, UK) supplemented with 10%  heat-inactivated 
(65°C for 1 hour) fetal calf serum (Sera-Lab, Crawley Down, Sussex, 
UK).  All  procedures were  performed on  cultures  assayed to  be 
greater than 95% viable by trypan blue exclusion. 
Preparation of bcr-ab1 In Vitro Transcripts 
Total RNA was purified by  a guanidine thiocyanatdacid phenol 
method36 from  KYOl  and K562 cell lines. Reverse transcription 
(RT) reactions were performed on 5 pg samples of RNA in 50 pL 
reactions using 20 U/pL superscript reverse transcriptase (GIBCO) 
and 3.3 pmol/L  random nonamers. Reactions were terminated by 
incubation at 90°C  for  5  minutes. One-hundred-microliter  “hot- 
start” polymerase chain reactions (PCRs) were performed by assem- 
bling  1 pL of  RT reaction and  1.25 pmoK (each) primers in 80 
pL 1  x buffer (Pfu  polymerase buffer 1; Stratagene, Cambridge, UK) 
below the solid wax barrier (pastillated wax, congealing point 60°C; 
BDH, Lutterworth, Leicestershire, UK), which was overlaid with 20 
pL of  1  X buffer containing 2.5  U native Pfu polymerase (Stratagene) 
and 1 mmol/L (each) dNTPs. The primers used were 5’:5‘ . . .  GGT 
ACC  TAA TAC GAC TCA CTA TAG GGA GAA GCT TGG AGC 
TGC AGA  TGC TGA CCA AC . . . 3‘  (bcr-specific portion at 
position 3227 to 3248 of HSBCR, accession no. Y00661) and 3‘:5‘ 
. . .  TGT  TGA CTG GCG TGA TGT AGT TGC “I . . .3’  (com- 
plementary to  c-abl positions 508 to 483 of HSABL, accession no. 
X16416). RT-PCR amplification of RNA extracted from KYOl cells 
gave a 393-bp b2a2 product, whereas amplification from K562 total 
RNA produced a 468-bp b3a2 DNA fragment. PCR products were 
purified  by organic solvent extraction and ethanol precipitation, fol- 
lowed by  resuspension in 20 pL 10 mmoVL  Tris-HC1,  1  mol/ 
L EDTA, pH 8.0, before nonradioactive cycle sequencing (fmole; 
Promega, Southampton, Hampshire, UK) using 5’  digoxigenin-la- 
beled  primers  (I) l7  promoter-specific 5‘ . . . Dig-TAA  TAC 
GAC TCA CTA TA . . . 3’  and (2) nested c-abl (complementary 7  46  GILES  ET AL 
Human  bcr-ab1 (b2-a2  type)  cDNA sequence 
5' ...  ATA  AGG  AAG  AAG  CCC TTC  ...  3' 
t 
Breakpoint 
b2-a2  antisense  oligodeoxynucleotides 
3'  ...  F-T-A-T  . T-C-C  -  T-T-C  -  T-T-C  -  G-G-G  -  A-A-G  .....  5' 
3'  .....  T/A/T /  T/C-C  -  T-T-C  -  T-T-C  -  G-G/G  /  A/A/G-F  ...  5' 
3' .....  T/A/T /  T/C/C /  T-T-C  -  T-T-C  /  G/G/G /  A/A/G-F ...  5' 
3'  .....  T/A/T /  T/C/C /  T/T-C  -  T-T/C /  G/G/G /  A/A/G-F ...  5' 
3'  ...  F-T*A*T *  T*C*C *  T*T*C *  T*T*C *  G*G*G *  A*A*G  .....  5' 
3'  ...  F-T/A/T /  T/C*C *  T*T*C *  T*T*C *  G*G/G /  A/A/G. ....  5' 
Human  bcr-ab1 (b3-a2  type) 
5'  ...  AGA GTT CAA AAG  CCC 
t 
Breakpoint 
CDNA  sequence 
TTC..  .3' 
b3-a2  antisense  oligodeoxynucleotides 
3' ...  F-T-C-T  -  C-A-A -  G-T-T  -  T-T-C  -  G-G-G  -  A-A-G  .....  5' 
3' .....  T/C/T /  C/A-A  -  G-T-T  . T-T-C  -  G-G/G  /  A/A/G-F  ...  5' 
3' .....  T/C/T /  C/A/A  /  G-T-T  . T-T-C  /  G/G/G /  A/A/G-F ...  5' 
3' .....  T/C/T /  C/A/A /  G/T-T  -  T-T/C  /  G/G/G /  A/A/G-F ...  5' 
3' ...  F-T*C*T *  C*A*A  G*T*T *  T*T*C *  G*G*G *  A*A*G  .....  5' 
3' ...F-  T/C/T /  C/A*A *  G*T*T  *  T*T*C *  G*G/G /  A/A/G..  .  .S' 
3'  ...  F-T/C/T /  C/A/A /  G*T*T *  T*T*C /  G/G/G /  A/A/G..  ...  5' 
3' ...  F-T/C/T /  C/A/A  /  G/T*T *  T*T/C /  G/G/G /  A/A/G..  ...S' 
code  5l-3' 
Code  5l-3' 
3B17pAS-3'F 
5'F-3B494AS 
5'F-3B656AS 
5'F-  3B73JAS 
3B17SAS-3'F 
3B49S4AS-3'F 
3B65S6AS-3'F 
3BJ3SJAS-3'F 
Fig 1.  Human bcr-ab/ oligodeoxynucleotide  structures  and  sequences.  A dash  (-)  between bases  indicates  the presence  of  a  normal 
phosphodiester  linkage,  whereas  a  slash  (I)  indicates  a  methylphosphonate  internucleoside  linkage  and  an  asterisk  (*) indicates  a  phosphoro- 
thioate linkage.  Fluorescein attachment to the 5' and  3' termini via  a 6-amino-l-hexanol-linker is indicated by -F  and  F-,  respectively.  The 
name  of  each  oligodeoxynucleotide  is  shown to  the right of the sequence  and  is derived from the structure and  sequence  as  below. The  series 
is shown by the first two alphanumerics "26  or "38".  indicating b2a2  and  b3e2  break  point targets,  respectively.  The next three or four 
alphanumerics indicate  structure in  the conventional 5' to 3' direction: "17p"  has all internucleoside  bonds  of the normal phosphodiester  type, 
"494" has four methylphosphonates at both termini and nine central  phosphodiesters, "65s6 has  six  methylphosphonates at each end  and 
five central phorphorothioatw, and "17s"  has  all internucleoside  linkages of the phosphorothioate  type.  The  next two characters  indicate 
actual sequence, "AS  being antisense.  Finally, "5'F-" and  "-3'"'  denote  fluorescein  attachment  to the 5' and 3' termini, respectively. 
to position 274 to 253 of  accession no. X16416) 5'  .  . . Dig-TCA 
GAC CCT GAG GCT CAA AGT C . . .3'. 
Transcripts containing low levels of  digoxigenin label were ob- 
tained as previously described"  using l7  RNA polymerase (Epicen- 
ter, UK Distributors Cambio). The RNAs were  purified  from tem- 
plate DNA and contaminating PCR primers, as described above for 
total RNA,36 and ethanol precipitated using linear polyacrylamide 
as  B3a2 transcripts were 434nt long, containing 152nt bcr 
and  282nt c-abl,  whereas b2a2 transcripts were 359nt long, con- 
taining 77nt bcr and 282nt c-abl. 
Preparation of Human Cell Extract 
Whole cell extract was obtained from the MOLT4 acute lympho- 
blastic leukemia cell line using the ammonium sulphate fractionation 
technique described by  Manle~.~~  Small aliquots (100 pL) of  the 
dialyzed final solution were stored in liquid nitrogen and could be 
thawed on  icehap frozen at least three  times before significant 
reduction of RNase H activity was evident. 
Cell Extract Assays 
Assays were conducted with 50 to  100  ng of digoxigenin-labeled 
transcript per  10 pL  of reaction at  37°C  in  an intracellular buffer 
(1 I  mmoVL potassium phosphate, pH  7.4,  108 mmoVL KC1,  22 
mmoVL NaCI, 1 mmol/L dithiothreitol, 3 mmoVL MgCI2, 1 mmol/L 
ATP) with 1 pmolfl, oligodeoxynucleotide, I U/pL human placental 
ribonuclease inhibitor (Stratagene) and 1 pg/pL yeast tRNA. Whole 
cell extract was added to  10% of  the final reaction volume. 
RNA analysis.  Samples (2 pL)  were removed at intervals to 200 
pL RNA extraction buffer containing 5 pg  linear polyacrylamide 
carrier. The phases were induced to separate by  addition of  25  pL 
chloroform and the RNA recovered from the upper, aqueous phase 
by  ethanol precipitation. The pellet obtained on centrifugation was 
resuspended in 20 pL  gel loading buffer (80% formamide, 90 mmoU 
L Tris-borate, 2 nmoyL EDTA, 0.05% Orange G, 0.05% Xylene 
Cyano]), heated to 95°C for 5 minutes, and quenched on ice, and 5 
pL  to 10 pL  was  loaded onto preheated (50°C) 20-cm length, 0.75- 
mm thick 7 moVL urea 6%  polyacrylamide (19:l acrylamide:N,N',- ANTISENSE OLIGO COMPARISON FOR  BCR-ABL  MRNA  7  41 
methylene bis-acrylamide) gels. Electrophoresis was conducted at a 
constant temperature and voltage  (50°C  and  500 V,  respectively) 
until the Orange G dye band had migrated -  19 cm (approximately 
1 hour).  Nucleic  acids  contained  in  the  gel  were  electroblotted 
(Trans-Blot Semidry cell; BioRad) onto Hybond N (Amersham, Lit- 
tle  Chalfont,  Buckinghamshire,  UK)  or  Nytran  NY12N 
(Schleicher & Schuell, UK Distributor Anderman & CO  Ltd, Kings- 
ton-Upon-Thames, Surrey, UK). Transfer was routinely checked by 
examining both gel and membrane for yeast tRNA UV shadowing. 
Membranes were placed to dry at 50°C  and subsequently UV cross- 
linked (h  = 254 nm, 2 minutes). Digoxigenin-labeled RNAs were 
detected using alkaline phosphatase-conjugated antidigoxigenin Fab 
fragments (Boehringer, Lewes, East Sussex, UK) and the chemilumi- 
nescent protocol recommended by the suppliers of the chemilumines- 
cent substrate CSPD (Tropix, UK  Suppliers Cambridge Bioscience, 
Cambridge, UK). Autoradiographs were scanned densitometrically 
using a Shimadzu CS9000 Flying Spot instrument (UK suppliers, 
VA Howe & CO Ltd. Banbury, Oxfordshire, UK). 
Oligodeoxynucleotide analysis.  Samples (2 pL) were removed 
to 10 pL ice-cold 10 mmoVL EDTA (pH 8.0). For polyacrylamide 
gel electrophoresis (PAGE) analysis, 3 pL aliquots (0.5 pmol oligo- 
deoxynucleotide) were mixed with 7  pL gel loading buffer (vide 
supra) treated as for RNA and fractionated by an identical electro- 
phoretic procedure, except that the gels used were 15% polyacryl- 
amide (rather than  6%). Nucleic acids contained in the  gel were 
electroblotted onto Nytran NY12N membrane, as described above. 
Inspection of the dried membrane under UV  illumination showed 
fluorescent compounds on the membrane surface. Detection of  fluo- 
rescein-labeled oligodeoxynucleotides and degradation products UV 
crosslinked to the  membrane (X  = 254 nm, 3 minutes) could be 
enhanced using an Wine  phosphatase-conjugated antifluorescein 
Fab fragment (Boehringer) and the chemiluminescent CSPD proto- 
col, as for digoxigenin-labeled RNA. Phosphorothioate and chimeric 
methylphosphonatdphosphorothioate oligodeoxynucleotides  pro- 
duced very poor chemiluminescent signals compared with analogous 
phosphodiester compounds, despite showing no greater tendency to 
elute from the membrane during processing. For HPLC analysis, 
oligodeoxynucleotides containing  six  or more  phosphodiester or 
phosphorothioate residues were analyzed by  weak anion exchange 
chromatography (MA7 plasmid column held at 65°C; BioRad) with 
a gradient of 0 to  1.5  mom  KC1 in 20 mmol/L potassium phosphate- 
buffered 50% formamide, pH 7.5, over 60 minutes at a  flow rate of 
1 Wmin.  Oligodeoxynucleotide analogues with fewer charges were 
analyzed by reverse-phase chromatography (Asahipak Shodex C8P- 
50 column; Asahi Chemical Industry CO  Ltd, UK Suppliers Prolabo, 
Manchester, UK) with a gradient of  5% to 50% acetonitrild0.1 mol/ 
L triethylammonium acetate (TEAA),  pH 8.0, over 20 minutes at a 
flow rate of  1 Wmin.  Aliquots (6 pL)  of the oligodeoxynucleotide- 
EDTA  solution (l pm01 oligomer) were diluted to  100 pL with 
the  appropriate weak buffer,  heated to 95°C for  5  minutes, and 
immediately injected onto the column. Fluorescent compounds in 
the column effluents were detected with a  1046A Programmable 
Fluorescence Detector (Hewlett Packard, UK  Suppliers Anachem, 
Luton, Bedfordshire, UK) with excitation and emission gratings set 
to 494 and 530 nm,  respectively. 
Reversible  Cell  Peneabilization With  Streptolysin  0 
KYOl and LAMA84 cells were treated with streptolysin 0 essen- 
tially according to the protocol of Barry et a139  as modified by Spiller 
and Tidd?’  Briefly, IO6  cells were washed in permeabilization buffer 
(137 mmolR. NaC1,  100 mmoVL  PIPES, pH  7.4,  5.6  mmoVL glu- 
cose, 2.7 mmoVL  KCl, 2.7  mmoVL  EGTA,  1 mmoVL ATP, 0.1% 
bovine semm albumin) and resuspended in 100 pL of preactivated 
(5  dithiothreitol, 1 mmoVL ATP, overnight) streptolysin 0 
solution (Sigma Chemical CO, Poole, Dorset, UK) in permeabiliza- 
tion buffer containing 0 or 20 pmoVL antisense oligodeoxynucleo- 
tide and incubated at 37°C for 20 minutes. Resealing was achieved 
by the addition of  1 mL RPM1 1640 medium containing 10% fetal 
calf serum and incubation was continued at 37°C for a further 220 
minutes before RNA extraction. All experiments were performed 
with duplicates for each oligodeoxynucleotide treatment and no oli- 
godeoxynucleotide control points. RNA was purified from experi- 
mental  cell  cultures  using  a  guanidine  thiocyanate/acid  phenol 
method.36 RNA precipitates were resuspended in  water and  their 
concentration was  estimated by  gel electrophoresis and ethidium 
bromide staining. 
Semiquantitative RT-PCR (SQRT-PCR) 
RNA (approximately 1 pg) was suspended in 4 pL  ddH20,  heated 
to  80°C  for  5  minutes, and  then placed  at  37°C  for  5  minutes. 
Ribonuclease Inhibitor (40  U;  Stratagene) and the RT primer  (2 
pmol) were added in native Pfu  polymerase PCR buffer, dithiothrei- 
to1 solution (final concentrations 1  X  and 10 mmoVL, respectively), 
and incubation continued at 37°C for 45 minutes. At the end of this 
period, 200 U superscript reverse transcriptase (GIBCO) and dNTPs 
(final concentration, 500  pmoVL  each)  were  added  in  IX PCR 
buffer, 10 mmoVL dithiothreitol (final reaction volume, 10 pL)  and 
incubation was extended for a further 45 minutes at 37°C. Reactions 
were stopped by heating to 95°C for 5 minutes followed by treatment 
with 1 ng RNase A (type III-A; Sigma) for 20 minutes at  37°C before 
PCR amplification. For PCR1, 10 pL 1X PCR buffer containing 20 
pm01 of each primer and 0.5 U  of native Pfu  polymerase was added 
to the inactivated RT reaction and overlaid with mineral oil before 
thermal cycling. For PCR2,  5 pL was taken from PCRl reactions 
and added to 15 pL 1  X PCR buffer containing 15 pmol sense primer, 
20 pm01 digoxigenin-tagged antisense primer, 0.5 U Pfu  polymerase, 
and 3 nmoI of each dNTP. Reactions were overlaid with mineral oil 
before subamplification. Semiquantitation was achieved by limiting 
the first PCR  round  to 15 cycles and the second PCR to 5 cycles. 
We have found the signal to be linear with input RNA over the 
range of  IO ng to 1 pg using this protocol (data not shown). Reverse 
transcription and  PCR primers were as follows: reverse transcription 
primer, 5’ TGT TGA CTG GCG TGA TGT AGT TGC ‘IT 3’; sense 
primer, 5’ GGT ACC TAA TAC GAC TCA CTA TAG GGA GAA 
GCT TGG AGC TGC AGA TGC TGA CCA AC 3’; PCRl antisense 
primer, 5’ AGA GAG GGA TCC AAC GAG CGG CTT CAC TCA 
G 3’;  nested-labeled PCR2 antisense primer, 5’ digoxigenin-TCA 
GAC CCT GAG GCT CAA AGT C  3’.  Final analysis of  SQRT- 
PCR  products  was  accomplished  by  electrophoresis  through 
0.75-mm thick 6% polyacrylamide sequencing gels, semidry electro- 
transfer (Trans-Blot; BioRad) onto Nytran NY12N membrane, and 
detection  by  antidigoxigenin-alkaline  phosphatase Fab  fragments 
with a  chromogenic procedure. The resultant blots were scanned 
densitometrically as previously describedm and each data point was 
normalized to the mean  of the duplicate “No Oligo” control values. 
The statistical significance of the results was calculated using single- 
variable ANOVA, as below. 
Computational  Methods 
The Sun network based Wisconsin GCG package was  used  for 
sequence analysis and manipulation. Sequences were obtained from 
Genbank using the  “Fetch”  program and manipulated to produce 
the required fragments via “Bestfit”  and “Seqed.”  RNA secondary 
structures were calculated using the “FoldRNA”  routine and graphi- 
cal display obtained by  piping this  output into the  “Squiggles” 
program. Single variable ANOVA was performed using the MICRO- 
TAB program running on an Archimedes 440. GlLES ET AL  748 
'OU1  nfl 
Oligodeoxynucleotide 
RESULTS AND  DISCUSSION 
To delineate the intracellular effects that might pertain 
during future bcr-ab1 antisense bone marrow purging experi- 
ments, we have looked at the interactions of  oligodeoxy- 
nucleotides,  bcr-ab1  RNA,  and  human  ribonuclease  H 
(RNase H) initially in cell-free systems under physiologic 
conditions. 
The In Vitro Test System 
All  of  the oligodeoxynucleotides and analogue structures 
used in these experiments were fluorescein labeled at either 
the 5' or 3'  termini, as depicted in Fig  1. The cell extracts 
containing RNase H enzymes were obtained from the human 
acute lymphoblastic leukemia cell line MOLT4 by  a pre- 
viously described procedure.'8 The RNase H activity in these 
crude cell extracts had a limited lifetime under  the assay 
conditions, presumably because of  progressive proteolytic 
destruction of the enzyme molecules. Consequently, the bars 
in, eg, Fig 2 represent total cleavage occurring before en- 
zyme decay. The bcr-ab1 target RNAs for these experiments 
were obtained by  in  vitro transcription of cDNA fragments 
derived from bcr-abl mRNAs by  RT-PCR, as described in 
the  Materials and  Methods. The  in  vitro  transcript RNA 
molecules were of different lengths depending on breakpoint 
type: b3a2 transcripts were 434nt long and b2a2 transcripts 
were 359nt long (data not shown). 
Methylphosphonate/Phosphodiester  Chimeric Analogues 
Can Be Eficient and  Specific Antisense Esfectors In  Vitro 
The ability of  the antisense oligodeoxynucleotides to di- 
rect crude human RNase H activities to cleave 359nt b2a2 or 
434nt b3a2 bcr-ab1 in vitro transcribed RNA was examined. 
Phosphorothioate (I~s),  phosphodiester (17p), and the range 
of chimeric methylphosphonate/phosphodiester oligodeoxy- 
nucleotide structures complementary to either the b2a2 or 
b3a2  sequences  were  studied  (structures, sequences, and 
names as shown in Fig 1). The results of  a representative 
experiment are presented in Fig 2. Oligodeoxynucleotide- 
Fig 2.  Human cell  extract  RNase  H  cleavage of 
bcr-ab/ RNA (434nt  b3a2  1.1  and  359nt  b2a2  [U])  di- 
rected  by  bw-ablphosphorothioate,  phosphodiester, 
and  chimeric  methylphosphonodiester/phospho- 
diester  antisense  oligodeoxynucleotides.  Digoxi- 
genin-labeled  RNA  was  incubated  at  37°C  for  30 
minutes  in  solutions  containing  10%  cell  extract  (by 
volume)  and  the indicated  oligodeoxynucleotide.  ND 
indicates  not  determined,  although  nontargeted 
cleavage of b3a2  RNA  in the presence of 2B17sAS- 
3'F oligodeoxynucleotide  was  apparent  on  visual  ex- 
amination  of the blot;  uncertainty  in the baseline 
assignment  under  the fragment  peak  on  the dendto- 
metric  trace  prevented  accurate  determination  of the 
extent of cleavage.  The  oiigodeoxynucleotide  struc- 
tures  and  sequences  are as shown  in  Fig 1. 
directed, cell extract RNase H-dependent scission of  the in 
vitro transcripts produced RNA fragments of approximately 
282nt (c-abl, a2)  and either 152nt (bcr,  b3) or 77nt (bcr, b2) 
depending on the target  RNA sequence. Substrate and  prod- 
uct  RNA fragments were fractionated by electrophoresis and 
imaged by  chemiluminescence and the extent of  cleavage 
quantitated by densitometry. The 17s, 17p, and chimeric 494 
(chimeric with  4  methylphosphonates at  each  end  and  9 
central phosphodiesters) b3a2 antisense oligodeoxynucleo- 
tides induced broadly equivalent levels of  cleavage at  the 
target site on b3a2 RNA (40% to 55%). Rather less target 
scission  (10%  to  15%) was  observed  with  the  chimeric 
3B656 structure (6 methylphosphonates at each termini, 5 
central  phosphodiester residues),  indicating that,  for  this 
RNA  target at least, the 656 structure may  be  expected to 
be  an  inefficient  antisense effector. In  contrast, the  b2a2 
RNA was efficiently cleaved (85%) at the target site by the 
b2a2 antisense sequence 656 chimeric oligodeoxynucleotide. 
Indeed, the extent of cleavage was  not substantially different 
from that obtained (90%  to 95%) with the homologous 494. 
17p,  and  17s compounds. At  no time was either b2a2  or 
b3a2 RNA cleaved by  human RNase H in the presence of 
chimeric 737 antisense oligomers (7 methylphosphonates at 
each end,  3 central phosphodiesters). This  finding  would 
appear to  reflect  a property of the human enzymes because 
in previous experiments 737 structure anti-bcr-ab1 effectors 
were  shown  to  be  capable  of  directing  Escherichia  coli 
RNase H to cut bcr-ab1 RNA targets (data not shown). 
The results presented in Fig 2 show that  both  phosphodies- 
ter and phosphorothioate  oligodeoxynucleotides  can promote 
undesired activity of  human RNase H in vitro because both 
structures directed cleavage of  nontarget sequence bcr-ab1 
RNAs. Much higher selectivity of  RNA  scission was  ob- 
served with the chimeric methylphosphonate/phosphodiester 
bcr-abl antisense effectors. Not one of  the chimeric struc- 
tures, of either sequence, induced detectable nontargeted en- 
zyme activity. In contrast, b2a2 RNA was digested by RNase 
H in  the  presence of  3B17pAS-3'F and 3B17sAS-3'F anti- 
sense oligodeoxynucleotides (to produce fragments consis- ANTISENSE OLIGO COMPARISON FOR BCR-ABL MRNA  749 
tively) may  be explained by  the differing secondary struc- 
tures of their target sites and by the low RNA hybridization 
potential of  oligodeoxynucleotides with  high  methylphos- 
phonate content?*'  which  limits their  capacity to  invade 
stable RNA duplexes. 
Fig 3.  Calculated secondary structures of bcr-sb1434nt b3a2 RNA 
(top) and 359nt b2a2 RNA (bottom). The breakpoints are indicated 
and may  be  seen to reside within a stable stem structure and an 
open loop region for b3a2 and b2a2, respectively.  The position of the 
b2-b3 exon boundary within b3a2 RNA is also indicated. 
tent with cleavage at the b2a2 breakpoint; data not shown) 
and b3a2 RNA  was  cut by RNase H in the presence of  the 
2B 17pAS-3'F oligodeoxynucleotide (to produce fragments 
consistent with some cleavage at the b3a2 breakpoint, but 
mostly at the junction between bcr exons b2 and b3; data 
not shown). It would thus appear that inappropriate cleavage 
by  human RNase H enzymes can occur, under physiologic 
conditions, at regions of  partial complementarity between 
RNA and oligodeoxynucleotides, as previously reported for 
E. coli RNase H.20.26 
Antisense EfJiciency May Be Limited by Target RNA 
Secondary  Structure 
One of the most striking aspects of the results presented 
in  Fig  2 is the substantial difference in maximal extent of 
cleavage of b2a2 and b3a2 RNAs, ie, 95% b2a2 RNA (SF- 
2B494AS) versus 55% b3a2 RNA (3B17pAS-3'F).  which 
may  reflect differences in target site accessibility. The calcu- 
lated secondary structures of the 434nt b3a2 and 359nt b2a2 
in vitro transcripts are presented in  Fig 3. It may be seen that 
the b3a2 breakpoint resides within a stable stem structure, 
whereas the b2a2 breakpoint is in an open loop region and 
may therefore be rather more accessible for hybridization to 
oligodeoxynucleotides. The even more significant difference 
in targeted activity obtained with  5'F-2B656AS  and  5'F- 
3B656AS oligodeoxynucleotides (85% and  15%, respec- 
Methylphosphonate/Phosphodiester  Chimeric  Analogues 
Are More Nuclease-Resistant Than Phosphodiester 
Compounds 
The stability of the oligodeoxynucleotides and analogues 
in cell extract was investigated, and the data are presented 
in  Fig  4.  Both  of  the 17p structures, previously reported"." 
to be effective antisense agents in the treatment of cells over 
periods of days to weeks,  can be seen to be  highly unstable, 
with  the b3a2  antisense oligodeoxynucleotide digested to 
completion within 30 minutes and the b2a2 antisense oligo- 
deoxynucleotide more  than  50% degraded after exposure 
for the same time. Such sequence dependent difference in 
nuclease sensitivity has been previously reported:'  Further- 
more,  it should be  noted that the 3' linkage of fluorescein to 
the phosphodiester oligodeoxynucleotides used in this study 
bestows resistance to 3'-5'  exonucleases (Tidd and Spiller, 
unpublished results), the major nuclease component of bio- 
logic fluids.l7*IR  Therefore, enzymatic digestion of these par- 
ticular phosphodiester oligodeoxynucleotides proceeds via 
an initial, rate-limiting endonucleolytic attack, which  is con- 
sistent with the HPLC traces presented. 
In  contrast, chimeric methylphosphonate/phosphodiester 
oligodeoxynucleotides  were  comparatively  stable  to  the 
nucleases found in cell extracts, with the 5'F-3B494AS com- 
pound  less  than  20%  degraded after  30 minutes and  the 
5'F-2B656AS less than 5% digested over the same period. 
Essentially  equivalent  results  were  obtained  for  5'F- 
2B494AS and SF-3B656AS oligodeoxynucleotides, respec- 
tively (data not shown). Reverse-phase HPLC and  polyacryl- 
amide gel electrophoresis indicated that both 737 structure 
chimeric analogues remained undegraded over the assay pe- 
riod (data not shown). The reduced sensitivity of chimeric 
methylphosphonodiester/phosphodiester  oligodeoxynucleo- 
tides to cellular endonucleases with increased methylphos- 
phonate substitution of phosphodiester internucleoside link- 
ages is in agreement with previously published data obtained 
with  purified  nucleases.27  The  3'-fluorescein-labeled  17s 
phosphorothioate oligodeoxynucleotides were also found to 
be completely stable for at least 30 minutes of  incubation 
with the cell extract (data not shown). 
Methylphosphonate/Phosphorothioate  Chimeric  Analogues 
Are ESJicient  and Specijic In Vitro and  Are 
Nuclease-Resistant 
It  appeared that efficient antisense activity against b3a2 
RNA  (Fig 2) required the oligodeoxynucleotide to possess 
more than five central phosphodiester residues, presumably 
to be able to invade the stable stem structure at the target 
site, (Fig 3) and yet chimeric 494 methylphosphonatelphos- 
phodiesters were not completely stable to nucleases (Fig 4). 
We therefore decided to replace the nuclease labile phospho- 
diester linkages within the chimeric structures with  relatively 750  GILES  ET AL 
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stable phosphorothioate internucleoside bonds to produce the 
recently  described3'  methylphosphonate/phosphorothioate 
chimeric  analogues.  The  b3a2  antisense  compounds, 
3B49s4AS-3'F (4 methylphosphonates at each end, 9 central 
phosphorothioate residues), 3B65s6AS-3'F, and 3B73s7AS- 
3'F, were  all found to be completely stable to the cell extract 
nucleases over the assay period when analyzed by  PAGE 
(data not shown) and weak anion exchange €"LC  (49s4 and 
65s6 only; Fig 4). 
The range of b3a2 antisense phosphorothioate and methyl- 
phosphonate/phosphorothioate  oligodeoxynucleotides were 
tested for activity at directing human RNase H cleavage of 
target b3a2 and nontarget b2a2 RNAs, and the results are 
presented in Fig 5. It may  be seen that the all-phosphorothio- 
ate analogue induced approximately 60% cleavage of  b3a2 
target, but also approximately 30% of  b2a2 RNA was inap- 
propriately digested, which is consistent with the previous 
observations (Fig 2). The chimeric methylphosphonate/phos- 
phorothioate oligodeoxynucleotide 3B49s4AS-3'F  induced 
approximately 45% cleavage of  b3a2 RNA,  a level of activ- 
Fig 4.  Weak  anion  axchange  HPLC  analysis  of oli- 
godeoxynucleotide  stability  in  10%  cell  extract  (by 
volume).  Samples  were  removed  from  standard 
assays after 0 and 30 minutes and  compared  with 
an  equal  amount  of  authentic oligodeoxynucleotide, 
middle,  back,  and  front respectively, within each  set 
of three  traces.  Oligodaoxynucleotide  stability  pre- 
sented 3617pASJ'F, bottom  left; ZBl7pAS-3'F.  bot- 
tom right; 5'F-3WS,  mid-left; ~'F-~B~SS~AS,  mid- 
right;  5'F-ZBWEAS.  top left; and ~'F-~B~SS~AS,  top 
right. The HPLC traces  show  detection  of fluomcent 
material  in  the column  effluent  against  time into the 
solvent  gradient. 
ity similar to that displayed by the congenic methylphospho- 
nate/phosphodiester compound, and displayed no apparent 
cross-reactivity with b2a2 RNA. No cleavage of b3a2 RNA 
was detectable in assays containing 3B6%6AS-3'F,  which 
may  reflect even lower ability than 5'F-3B656AS to invade 
the target RNA  secondary structure. The  phosphorothioate 
modification is moderately  helix destabilizing*' and replace- 
ment of  the phosphodiester section in methylphosphonate/ 
phosphodiester chimeric oligodeoxynucleotides with  phos- 
phorothioates would be expected to result in further reduc- 
tion of hybridization potential. The 73s7 structure proved to 
be inactive at directing human RNase H, as expected. 
Antisense Oligodeoxynucleotide Activity In Vivo 
It  is  evident that the  most  clinically relevant antisense 
effects are those that pertain within living cells. A procedure 
was  developed that  allowed  in  vivo  antisense effects  to 
be  obtained  and  quantified. We  have  previously  shown 
that  reversible  cell  permeabiiization  with  streptolysin 0 
is a  relatively nontoxic method that efficiently introduces ANTISENSE OLIGO COMPARISON FOR  BCR-ABL MRNA  751 
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Fig 5.  Human cell extract RNase H cleavage of bcr-eblRNA i434nt 
b3a2 [MI  and  359nt  b2a2 [ON directed  by  bcr-ablb3a2  phosphorothio- 
ate and  chimeric  methylphosphonatelphosphorothioate antisense 
oligodeooxynucleotides.  Digoxigenin-labeled  RNA was incubated at 
37°C for 30  minutes in solutions  containing 10% cell extract (by  vol- 
ume) andthe indicated  oligodeoxynucleotide.  The oligodeoxynucleo- 
tide  structures  and  sequences  are as shown in Fig 1. 
oligodeoxynucleotides into cells3*  and that eels loaded with 
antisense effectors in this way readily show RNase H-depen- 
dent antisense effects!.” 
Human chronic myeloid leukemia KYOl (express b2a2 
breakpoint  bcr-ab1 mRNA)  and  LAMA84  (express b3a2 
breakpoint bcr-ab1 mRNA) cells  were  biochemically mi- 
croinjected  with  antisense  oligodeoxynucleotides,  using 
streptolysin 0.32  The effect on bcr-ab1 mRNA level 4  hours 
after introduction of the antisense effectors was analyzed by 
SQRT-PCR. The results presented in Fig 6 show the in vivo 
activity of  bcr-abl18-mer b2a2 and b3a2 antisense, chimeric 
methylphosphonate/phosphodiester 494,  chimeric  methyl- 
phosphonate/phosphorothioate 49~4,  and all-phosphodiester 
and all-phosphorothioate oligodeoxynucleotides (Fig 1). The 
histograms show mean bcr-ab1 mRNA level (as analyzed by 
SQRT-PCR) 2 the standard error (12 data points for each 
bar) relative to the  “No  Oligo”  control cells. The graph 
was compiled from the results of  three separate antisense 
experiments (for both the KYOl and LAMA84 cell lines); 
all  experiments contained duplicates  of  each  oligodeoxy- 
nucleotide and  “No  Oligo”  (control) treatments; and the 
level of  bcr-ab1 mRNA, in the total RNA prepared from 
every cellular treatment, was measured by two independent 
SQRT-PCRs. The intensities of  the SQRT-PCR signals on 
each blot were determined by densitometry and each point 
was normalized to the mean of  the duplicate “No Oligo” 
values on that blot, thus permitting comparison between the 
separate analyses and experiments. 
In  addition  to the  two  different  bcr-ab2  antisense  se- 
quences acting as controls for each other in  these experi- 
ments, extensive control experiments have been previously 
performed and the data obtained were included in  an earlier 
report.’  The bcr-ab1 oligodeoxynucleotides were shown to 
be  specific for bcr-ab1 mRNA  in  vivo. Under conditions 
that permitted efficient antisense b2a2 oligodeoxynucleotide- 
mediated,  RNase H-dependent  scission  of  b2a2  bcr-ab1 
mRNA in streptolysin 0-permeabilized KYOl cells, no vari- 
ation in the level of either c-myc or p53 nontarget mRNAs 
was induced by either b2a2 or b3a2 antisense effectors. Fur- 
thermore, suppression of b2a2 bcr-abl mRNA  in KYOl cells 
was selective to b2a2 antisense oligodeoxynucleotides. Both 
c-myc and  p53  antisense oligodeoxynucleotides caused  a 
substantial reduction in the level of  their respective target 
mRNAs when biochemically microinjected into KYOl cells 
but no effect on bcr-ab1 mRNA level was observed in either 
case. 
All four b2a2 antisense structures were effective at reduc- 
ing b2a2 bcr-abl mRNA expression within KYOl cells, as 
shown in Fig 6A. Of these four oligodeoxynucleotides, it is 
evident that  5IF-2B494AS was  the most  active antisense 
effector, reducing the  level  of  bcr-ab1 mRNA  to  around 
5% of  that  in  the  “No  0ligo”-treated  controls  and  that 
the chimeric methylphosphonate/phosphorothioate  analogue 
(2B49s4AS-3’F) was the least effective (mRNA level ap- 
proximately 33% of  control), a difference that was statisti- 
cally significant at the 0.1% level. The 17p and 17s structures 
may be seen to possess intermediate activities, with the phos- 
phorothioate analogue somewhat less active than the phos- 
phodiester oligodeoxynucleotide. Not one of  the b3a2 tar- 
geted oligodeoxynucleotides induced a substantial reduction 
in  b2a2  bcr-ab1 mRNA  expression in  KYOl  cells  (none 
different from the  “No Oligo”  control at the  1% level of 
significance). 
On the other hand, as can be seen from Fig 6B, not one 
of  the b2a2 antisense oligodeoxynucleotides reduced the ex- 
pression of b3a2 bcr-ab1 mRNA  in  LAMA84 cells by  any 
significant extent. B3a2 bcr-ab1 mRNA level was substan- 
tially lowered in LAMA84 cells treated with the 3B17pAS- 
3‘F and 5’F-3B494AS (to approximately 30% of  the  “No 
Oligo”  control level). The b3a2-targeted all-phosphorothio- 
ate antisense effector was significantly (P  1%) less effec- 
tive than the homologous all-phosphodiester and chimeric 
494  compounds  at  reducing  the  level  of  target  bcr-ab1 
mRNA  (approximately 59%  of  the  “No  Oligo”  control 
level).  The  chimeric  methylphosphonate/phosphorothioate 
b3a2 oligodeoxynucleotide (3B49s4AS-3’F) was inactive as 
an antisense agent in that it induced no  statistically signifi- 
cant reduction in the level of its target b3a2 bcr-ab1 mRNA 
when introduced into LAMA84 cells. 
It is evident from comparing Fig 6A and B that the anti- 
sense effects obtained in  the two different cell lines were 
not equally efficient. For example, the best antisense effect 
obtained in  LAMA84 cells  (with  3B17pAS-3‘F and 5’F- 
3B494AS) was a reduction of bcr-ab1 mRNA level to around 
30% of the “No Oligo”  control, whereas the least efficient 
b2a2 antisense effector (2B49s4AS-3’F) caused a reduction 
of  mRNA  level  in  KYOl  cells to  approximately 33%  of 
control. Such data are  consistent with the in  vitro results 
(Fig 2) that indicated that the b3a2 sequence was “difficult” 752  GILES  ET AL 
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Fig 6.  Antisense  oligodeoxynucleotide  effects in vivo.  Antisense  oligodeoxynucleotides  (20  pmollLl were introduced into human  chronic 
myeloid leukemia (A) WO1 and (B) LAMA84 cells using streptolysin 0 reversible  permeabilization.  The effect  on  bcr-eblmRNA  was  determined 
by SQRT-PCR 4 hours  after the oligodeoxynucleotides  were introduced into the cells  cytoplasm.  Three  experiments  were  performed  on each 
cell line;  all experiments contained duplicates of  each oligodeoxynucleotide treatment and ”No  Ollgo”  control and the intact bCr-Ub/ mRNA 
level in all of the total RNAs,  purified from the experimental cells,  was  determined  twice  l2 independent SQRT-PCR amplifications). SQRT- 
PCR  signal  was  normalized  to the mean of the duplicate  “No  Oligo” controls for each  analysis  and  expressed  as percentages.  The  histograms 
show  mean f  standard  error  of the SQRT-PCR-determined bcr-86/ mRNA level. It is clear that  in  (A)  the b2aZ bcr-ab/ mRNA level  was  reduced 
in  WO1 cells treated with the oligodeoxynucleotides 2B17pAS-3’F,  5’F-2B494AS,  ZB49s4AS-3’F.  and 2B17sAS-3’F.  whereas  in (B) the b3a2 
bcr-ab/  mRNA level was only substantially reduced in LAMA84 cells treated with the antisense  effectors  3617pAS-3‘F  and  5‘F-3B494AS.  The 
oligodeoxynucleotide  structures  and  sequences  are as described in Fig 1. 
and  that b2a2 RNA sequence was “easy”  to  target for anti- 
sense effects, and so would  be consistent with the full-length 
mRNAs possessing secondary structures in the region of the 
breakpoints, similar to those calculated for their respective 
in vitro transcripts (Fig 3). 
Overall, it  appears  clear  that  the  oligodeoxynucleotide 
structures may be ranked for their ability to reduce the ex- 
pression of bcr-ab1 mRNA in vivo 4 hours after introduction 
into the human KYOl (Fig 6A) and LAMA84 (Fig 6B) cells 
as chimeric methylphosphonate/phosphodiester  2  phospho- 
diester > phosphorothioate > chimeric methylphosphonate/ 
phosphorothioate. We have previously reported that phos- 
phorothioate  oligodeoxynucleotides can  show  reduced  in 
vivo antisense activity compared with phosphodiester and 
chimeric  methylphosphonate/phosphodiester  effectors,”  a 
finding supported by the data of Fig 6. It is  not  clear precisely 
why this occurs, although it may  be  related to the tendency 
of phosphorothioate oligodeoxynucleotides to bind nonspe- 
cifically to proteins$22-25  which  would  be  expected to reduce 
their solution concentrations and which also results in direct 
inhibition of  human  RNases H.25  Chimeric methylphospho- 
nate/phosphorothioate oligodeoxynucleotides, in  addition, 
may  be  expected to have reduced ability to  invade RNA 
duplexes, because of the reduced RNA hybridization poten- 
tial of  antisense analogues that contain methylphosphonate 
internucleoside  linkage^.^.'^ The inactivity of  the antisense 
reagent 3B49s4AS-3‘F at reducing the level of  b3a2 bcr- 
ab1 mRNA in LAMA84 cells may, therefore, result from a 
combination of (1) “difficult”  target RNA secondary struc- 
ture, (2) low ability of  the oligodeoxynucleotide to invade 
RNA secondary structure, (3) low solution concentration of 
the effector, and (4) direct inhibition of  endogenous RNase 
H. In  contrast, the comparatively nuclease-sensitive phos- 
phodiester and chimeric methylphosphonate/phosphodiester 
oligodeoxynucleotides were found to be the  most active anti- 
sense structures in vivo. The chimeric methylphosphonate/ 
phosphodiester 494 compound was more active than the ho- 
mologous phosphodiester structure at reducing the expres- 
sion of  the accessible (Fig 3) b2a2 mRNA, 4 hours after 
treating the cells. We suggest that  the  5’F-2B494AS  struc- 
tures moderately reduced ability to invade RNA secondary 
structures relative to 2B17pAS-3‘F (resulting from its re- 
duced RNA hybrid ~tability~.’~)  was  more than compensated 
by  its substantially increased resistance to nucleases (Fig 4 
and Tidd and Warenius”), permitting greater overall activity. 
Conclusions 
The data presented here are consistent with the view  that 
target secondary structure (Fig 3) can significantly influence 
the overall level of  antisense effect achieved, both in vitro 
(Figs 2 and 5) and in vivo (Fig 6). The b3a2 breakpoint type 
mRNA appears to be a more difficult target  than  the b2a2 
breakpoint  mRNA.  The  best  reduction  in  b3a2  bcr-ab/ 
mRNA level achieved in vivo was to approximately 30% of ANTISENSE OLIGO  COMPARISON FOR  BCR-ABL MRNA  753 
the  “No  Oligo”  control  (Fig 6) compared with  approxi- 
mately 5% with b2a2 mRNA. Greater activity at such recal- 
citrant targets might be obtained using oligodeoxynucleotide 
analogue structures that generate enhanced heteroduplex sta- 
bility, such as 2’-O-methyl/phosphodiester chimeric mole- 
cule~~’  or oligodeoxynucleotide analogues with 5-propyne- 
modified pyrimidine bases.42A3  However, it is not clear what 
degree of selectivity would be obtained in vivo with these 
analogues that bind to RNA  very  tightly. The in vitro data 
presented here (Figs 2 and 5) and  elsewhere20.z6  show that 
nontargeted activation of  RNase H can correlate with  in- 
creased RNA  heteroduplex stability. On the other hand, it 
appears quite clear that living human cells are more stringent 
than our in vitro human cell extract system (compare Figs 
2 and 6), perhaps due to RNAs being masked by  protein to 
a greater extent in vivo.  No  significant undesired antisense 
effect was observed with any of  the oligodeoxynucleotides 
tested either in KYOl or LAMA84 cells (Fig 6). 
Of the oligodeoxynucleotides tested, we conclude that the 
chimeric 494 methylphosphonate/phosphodiester  analogues 
represent the optimum structure type for targeting bcr-abl 
mRNA in vivo. More highly methylphosphonate-modified 
compounds (eg, 656s) can  show reduced activity in  vitro 
(Fig 2) and so may  be expected to be inefficient in  vivo. 
Phosphorothioate  and  chimeric  methylphosphonate/phos- 
phorothioate”  antisense effectors were shown to be signifi- 
cantly less active in vivo than chimeric methylphosphonate/ 
phosphodiester oligodeoxynucleotides (Fig 6), particularly 
against  b3a2  breakpoint mRNA.  Indeed, when  LAMA84 
cells were treated with 3B17sAS-3’F, the level of  bcr-ab1 
mRNA remained at  nearly  60% of  that in the control cells 
(which were streptolysin 0 treated in the absence of oligo- 
deoxynucleotide) 4 hours after they were loaded with large 
quantities of  3B  17sAS-3‘F. In contrast, the phosphodiester 
oligodeoxynucleotides were found to be effective at reducing 
the level of bcr-ab/ mRNA in the short term (Fig 6), but 
have  been  generally di~counted~,~”~  as potential antisense 
effectors for long-term treatments in vivo because of  their 
sensitivity to  nucleases (Fig 4  and  Tidd  and  Warenius,I7 
Abramova et  al,”  and Hoke et all’).  Data recently obtained 
with  antisense effectors  biochemically microinjected into 
CML cells showed that phosphodiester oligodeoxynucleo- 
tides were more rapidly degraded by nucleases than chimeric 
methylphosphonate/phosphodiester  analogues in  vivo. The 
3’ end-protected b2a2 antisense phosphodiester oligodeoxy- 
nucleotide  (2B17pAS-3’F) possessed  an  in  vivo half  life 
(tl,Z)  conservatively calculated at 30 minutes, whereas the 
chimeric congener S’F-2B494AS displayed a tllz of approxi- 
mately 2 hours (data not  shown).  In addition, it was found 
that  the  anti-b3a2  phosphodiester  oligodeoxynucleotide 
(3B 17pAS-3‘F) was  degraded  substantially  more  rapidly 
than  the  equivalent  anti-b2a2 structure in  vivo  (data  not 
shown), as was also noticed in vitro (Fig 4). Chimeric meth- 
ylphosphonate/phosphodiester antisense effectors show the 
optimum combination of activity and resistance to nucleases 
for targeting bcr-ab1 mRNA in vivo of the compounds tested 
here. 
This work is part of a critical evaluation of the therapeutic 
potential of antisense oligodeoxynucleotide analogues as ex 
vivo purging agents in  the treatment of  CML. On the basis 
of the results presented, we strongly suggest that the chimeric 
compounds described above possess antisense characteristics 
superior to those of analogues previously investigated for 
this purpose. However, it  is  not clear whether any oligode- 
oxynucleotide or analogue structure yet devised can achieve 
pharmacologically relevant intracellular concentrations with- 
out nonphysiologic manipulation of the cells. The uptake of 
antisense oligodeoxynucleotides into primary human leukae- 
mia cells has been investigated (Broughton et al, manuscript 
submitted) and was found to be as inefficient as was pre- 
viously reported for human leukemia cell lines7; in  both 
cases a vesicular localization of  oligodeoxynucleotide was 
observed. We have not  obtained antisense effects in  vivo 
with  any  of the compounds described in this report without 
using streptolysin 0 to biochemically microinject them into 
the cells. This finding is in line with an increasing number of 
reports stating that special steps need  to  be  taken  to  introduce 
oligodeoxynucleotides into a cells cytoplasm before reliable 
antisense effects may be achieved:’-%  We are currently in- 
vestigating  oligodeoxynucleotide  modifications  that  may 
permit cytoplasmic and  nuclear loadings to  be obtained with- 
out such special treatment of the cells. 
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